Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 757 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active then Sham Treatment Clear all
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 12, 2026, 7:09 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 3 Interventional

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

NCT00998218
View directory record Official record
Conditions
Sudden Cardiac Death, Ventricular Arrythmias
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Aspirus Heart and Vascular Institute-Research and Education
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Wausau, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 12, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

NCT06237868
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
rTMS Active, rTMS Sham
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 4 Interventional Results available

Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression

NCT00305578
View directory record Official record
Conditions
Bipolar Depression
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phyllantus Amarus for the Protection of Liver Health

NCT03349697
View directory record Official record
Conditions
Healthy
Interventions
Phyllantus amarus, Placebo
Dietary Supplement · Other
Lead sponsor
Biotropics Malaysia Berhad
Industry
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

NCT00806260
View directory record Official record
Conditions
Overweight, Obesity
Interventions
VI-0521, Placebo, Alcohol, alcohol placebo
Drug · Other
Lead sponsor
VIVUS LLC
Industry
Eligibility
21 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Not applicable Interventional Results available

Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study

NCT03521089
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment, Neurocognitive Dysfunction
Interventions
Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Not applicable Interventional

Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery

NCT05384860
View directory record Official record
Conditions
Acupuncture, Hip Surgery, Opioid Use
Interventions
Auricular Trauma Protocol (ATP) Acupuncture, No Acupuncture Group
Device · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 12, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Mechanisms Of Orbitofrontal Stimulation in Depression

NCT07230990
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Sham TMS, Active TMS
Device
Lead sponsor
Subha Subramanian
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 2 Interventional Results available

Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder

NCT02484456
View directory record Official record
Conditions
Major Depression
Interventions
AV 101 (4-Chlorokynurenine), Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT02169583
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 12, 2026, 7:09 AM EDT
Terminated Phase 4 Interventional Results available

Pregabalin for Abdominal Pain From Adhesions

NCT00310765
View directory record Official record
Conditions
Abdominal Pain, Surgical Adhesions
Interventions
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks, Placebo first followed by open label pregabalin
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.

NCT06305637
View directory record Official record
Conditions
Tinea Versicolor
Interventions
Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 12, 2026, 7:09 AM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT03926130
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab, Ustekinumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
15 Years to 80 Years
Enrollment
1,158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
140
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 12, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional

Renal Pelvic Denervation Pilot Trial

NCT07005050
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RPD, Active hypertension medical therapy
Device · Drug
Lead sponsor
Verve Medical, Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Surprise, Arizona • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 12, 2026, 7:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation

NCT07188376
View directory record Official record
Conditions
Alcohol Risk Behaviors
Interventions
Intermittent Theta Burst Stimulation, Continuous Theta Burst Stimulation, Sham Transcranial Magnetic Stimulation
Device
Lead sponsor
Michael J. Wesley, PhD
Other
Eligibility
21 Years to 29 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 12, 2026, 7:09 AM EDT
Withdrawn Early Phase 1 Interventional

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

NCT02878538
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Deferiprone, Placebo phase
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 12, 2026, 7:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

NCT03701555
View directory record Official record
Conditions
Digestive System Disease
Interventions
PvP001 placebo, PvP001 100 mg, PvP001 300 mg, PvP001 900 mg, Maximum Feasible Dose (MFD) of PvP002, Maximum Tolerated Dose (MTD) of PvP001, MTD of PvP001 following 7 days of PPI treatment, PvP002 placebo, PvP001 600 mg, PvP003 placebo, PvP003, PvP003 150 mg
Other · Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 12, 2026, 7:09 AM EDT
Not yet recruiting Early Phase 1 Interventional

Cholinergic Enhancement of Theta

NCT07228338
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
Interventions
COBENFY KarXT (50/20 mg), Control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 12, 2026, 7:09 AM EDT